ESMO26 Highlights an International Investigator-Led Study in First-Line RCC - Elizabeth Nally @BethN01 @crisbergerot oncodaily.com/voices/elizabe…

HARMONi-GI1 Shows Improved Overall Survival With Ivonescimab in Advanced BTC - Sakditad Saowapa @SakditadMD oncodaily.com/science/sakdit…

ENZARAD Results Raise Questions About Enzalutamide With ADT and Radiotherapy - Jarad Martin @DocJarad oncodaily.com/science/jarad-…

MSK Investigates a Novel MMAE Binder to Mitigate Neuropathy in Urothelial Cancer - David Aggen oncodaily.com/voices/david-a…

Benjamin Maughan Presents PAPMET2 Findings in Papillary RCC - Karine Tawagi @DrKarineTawagi oncodaily.com/science/karine…

Phase II REPRINT: Enfortumab Vedotin Plus Pembrolizumab in Rare Renal Carcinomas At the ESMO Congress 2026, Giuseppe Procopio presented preliminary first-stage results from the Phase II REPRINT trial (NCT06302569), evaluating enfortumab vedotin plus pembrolizumab in patients with collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC). Key findings: ▫️ Study population: 13 patients enrolled; nine evaluable after central pathological review (seven CDC and two RCCU-MP). ▫️ Objective response rate: 22% (2/9), with both responses occurring in patients with SMARCB1-deficient RCCU-MP. No objective responses were observed in CDC (0/7). ▫️ Disease control rate: 55% (5/9), including two partial responses and three cases of stable disease. ▫️ Median PFS: 5.2 months (95% CI 3.4–not reached). ▫️ Safety: No Grade 3–4 adverse events were reported. ▫️ Biomarkers: Both responding tumours were negative for membranous NECTIN-4 expression. Takeaway: REPRINT demonstrated preliminary antitumour activity and met the prespecified criteria to proceed beyond the first stage of Simon’s two-stage design. The findings are encouraging in the small RCCU-MP subgroup, but further evaluation is needed to establish efficacy and safety. @g_procopio_ @oncodaily @myESMO oncodaily.com/genitourinary-… #ESMO2026 #REPRINT #RenalMedullaryCarcinoma

Ivonescimab Shows Promising Activity in IMDC Good-Risk Renal Cell Carcinoma - Tom Powles @tompowles1 oncodaily.com/science/tom-po…

ESMO26 Showcases VOLGA Trial Findings Published in NEJM - Lazar Popovic @LazarPo31787807 oncodaily.com/voices/lazar-p…

ESMO26 Highlights JNJ-6143’s First-in-Class Approach to Targeting Prostate Cancer - Mark Wildgust @MAWildgust oncodaily.com/science/mark-w…

Phase III LITESPARK-011: Health-Related Quality of Life and Clinical Outcomes in Advanced RCC At ESMO Congress 2026, Daniel Heng presented a post hoc analysis of LITESPARK-011 (3595RO), examining associations between health-related quality of life (HRQoL), progression-free survival (PFS), and overall survival (OS) in patients with advanced clear cell renal cell carcinoma following anti–PD-(L)1 therapy. Key findings: ▫️ 741 patients were included in the exploratory analysis. ▫️ Baseline HRQoL: Higher FKSI-DRS scores were associated with more favourable PFS (HR 0.86; 95% CI 0.81–0.91) and OS (HR 0.81; 95% CI 0.77–0.86). ▫️ Longitudinal HRQoL: Higher FKSI-DRS scores over time were associated with more favourable PFS (HR 0.82; 95% CI 0.76–0.89) and OS (HR 0.57; 95% CI 0.52–0.62). ▫️ Landmark analyses: OS hazard-ratio estimates generally favoured stable or improved HRQoL at Weeks 13, 25, and 53, while PFS associations were less consistent. Takeaway: Higher baseline HRQoL scores and favourable HRQoL changes during treatment were generally associated with better clinical outcomes, particularly OS. These exploratory findings demonstrate associations and do not establish causation. @DrDanielHeng @motzermd @AndreaNecchi oncodaily.com/genitourinary-… #ESMO2026 #LITESPARK011 #RCC

RAMPART: Quality-of-Life Outcomes With Adjuvant Durvalumab in Resected RCC At ESMO Congress 2026, Sophie Merrick presented patient-reported outcomes from the RAMPART trial (3590RO), comparing adjuvant durvalumab with active monitoring in 218 patients with resected renal cell carcinoma. Key findings: ▫️ Primary QoL endpoint: No evidence of a difference in overall health and quality of life (OHQL) between groups at Month 15. ▫️ Week 16: Durvalumab was associated with clinically meaningful worsening in OHQL (−7.4), role functioning (−7.1), cognitive functioning (−5.3), fatigue (+5.5), and appetite loss (+5.8). ▫️ Month 15: Differences persisted in cognitive functioning (−7.1) and appetite loss (+7.4), with later worsening in dyspnoea (+7.5) and constipation (+12.2). Takeaway: Although the primary QoL endpoint showed no evidence of a difference, exploratory domain-specific analyses identified clinically meaningful effects during and after adjuvant durvalumab treatment. These findings require cautious interpretation, particularly the single-item dyspnoea and constipation outcomes. @tompowles1 @oncodaily @myESMO oncodaily.com/genitourinary-… #ESMO2026 #RAMPART #OncoDaily

Phase III KEYNOTE-564: Final Analysis of Adjuvant Pembrolizumab in Clear Cell RCC At ESMO 2026, Toni K. Choueiri presented the final protocol-prespecified analysis of the Phase III KEYNOTE-564 trial (3589RO), evaluating adjuvant pembrolizumab versus placebo in 994 patients with ccRCC at increased risk of recurrence following surgery. Key findings: ▫️ Median follow-up: 85.9 months. ▫️ 7-year DFS: 57.2% vs 44.6% (HR 0.68; 95% CI 0.56–0.82). ▫️ 7-year OS: 82.3% vs 76.6% (HR 0.70; 95% CI 0.53–0.92). ▫️ Subgroup analyses: DFS and OS findings remained consistent with earlier reports across key risk groups and sarcomatoid features. ▫️ Safety: No new safety signals or serious treatment-related adverse events were reported. Takeaway: After approximately seven years of follow-up, adjuvant pembrolizumab maintained its previously established DFS and OS benefits, reinforcing its role as a standard of care for patients with ccRCC at increased risk of recurrence after nephrectomy. @DrChoueiri @tompowles1 @oncodaily @myESMO oncodaily.com/genitourinary-… #ESMO2026 #KEYNOTE564

Phase III LITESPARK-011: Final Analysis of Belzutifan Plus Lenvatinib in Advanced RCC At ESMO 2026, Daniel Y. Heng presented the final analysis of LITESPARK-011 (3587O), evaluating belzutifan plus lenvatinib versus cabozantinib in advanced clear cell RCC following anti–PD-(L)1 therapy. Key findings: ▫️ Median PFS: 14.8 vs 10.8 months (HR 0.74; 95% CI 0.62–0.88). ▫️ ORR: 53.1% vs 40.2%. ▫️ Median OS: 33.7 vs 28.6 months (HR 0.85; 95% CI 0.70–1.03); the prespecified statistical significance threshold was not met. ▫️ Grade ≥3 TEAEs: 85.4% vs 83.0%. Takeaway: Belzutifan plus lenvatinib maintained the previously established PFS and ORR benefits over cabozantinib, while the final OS analysis did not demonstrate a statistically significant improvement. @motzermd @DrIacovelli @AndreaNecchi @oncodaily @myESMO oncodaily.com/genitourinary-… #ESMO26 #LITESPARK011 #RCC #OncoDaily

Phase III LITESPARK-012: Belzutifan or Quavonlimab Plus Pembrolizumab and Lenvatinib in Advanced RCC At ESMO 2026, Toni K. Choueiri presented results from the Phase III LITESPARK-012 trial (3586O), evaluating two investigational combinations versus pembrolizumab plus lenvatinib in previously untreated advanced clear cell RCC. Key findings: ▫️ Median PFS: 20.8 months with belzutifan + pembrolizumab + lenvatinib, 20.7 months with MK-1308A + lenvatinib, versus 23.7 months with control. ▫️ Overall survival: Neither investigational regimen demonstrated a significant improvement. ▫️ ORR: 69.1% and 69.0% versus 76.3% with control. ▫️ Adverse-event-related drug discontinuation: 51.6% and 51.4% versus 36.2%. Takeaway: Adding belzutifan or quavonlimab did not improve efficacy. Pembrolizumab plus lenvatinib remains a first-line standard-of-care option for advanced clear cell RCC. @DrChoueiri @tompowles1 @oncodaily @myESMO oncodaily.com/genitourinary-… #ESMO2026 #LITESPARK012 #RCC

Alfonso Gómez de Liaño Shares EV-304 Findings on Quality of Life in MIBC - Daniel Castellano @cdanicas @Uro_Oncologist oncodaily.com/science/daniel…

DASL-HiCaP Advances Evidence for Darolutamide in High-Risk Prostate Cancer - Jeff Ryckman @jryckman3 oncodaily.com/science/jeff-r…

Phase III DASL-HiCaP: Darolutamide Plus ADT and Radiotherapy in Very High-Risk Prostate Cancer At ESMO 2026, Tamim Niazi presented the interim results of the Phase III DASL-HiCaP trial (LBA4), evaluating darolutamide versus placebo added to ADT and definitive or salvage radiotherapy. Key findings: ▫️ 4-year MFS-CI: 95% vs 88% (HR 0.42; 95% CI 0.27–0.66; p=0.0001). ▫️ 4-year PSA-PFS: 91% vs 83% (HR 0.47; 95% CI 0.33–0.67). ▫️ Time to subsequent hormonal therapy: HR 0.36 (95% CI 0.21–0.60). ▫️ Overall survival: HR 0.88 (95% CI 0.49–1.59); no statistically significant benefit established. Takeaway: Adding darolutamide to ADT and locoregional radiotherapy significantly improved metastasis-free survival in very high-risk prostate cancer. Longer follow-up is needed to assess overall survival. @oncodaily @myESMO oncodaily.com/genitourinary-… #ESMO26 #ESMO2026 #DASLHiCaP #OncoDaily

Phase III VOLGA: Perioperative Durvalumab Plus Enfortumab Vedotin in MIBC At ESMO 2026, Thomas B. Powles presented results from the Phase III VOLGA trial (LBA2), evaluating perioperative durvalumab ± tremelimumab plus neoadjuvant enfortumab vedotin (EV) versus control in cisplatin-ineligible or cisplatin-refusing patients with MIBC. Key findings: ▫️ D+EV vs control: Significant EFS improvement (HR 0.51; p<0.0001); 24-month EFS 64% vs 45%. ▫️ OS: Significant benefit with D+EV (HR 0.58; p=0.0027); 24-month OS 78% vs 69%. ▫️ pCR: 45% vs 10% with D+EV versus control (local review). ▫️ D+T+EV: Improved EFS (HR 0.61; p=0.0004), but OS did not meet statistical significance. ▫️ Safety: Grade 3–4 treatment-related AEs occurred in 30% with D+EV and 42% with D+T+EV. Takeaway: VOLGA met both primary EFS endpoints, with a significant OS benefit demonstrated for D+EV versus control, supporting its potential as a new standard-of-care option. @tompowles1 @drenriquegrande @oncodaily @myESMO oncodaily.com/genitourinary-… #ESMO26 #ESMO2026 #VOLGA

Phase III NIAGARA: Molecular Subtypes and EFS Outcomes With Perioperative Durvalumab in Bladder Cancer At #ESMO26, Matthew D. Galsky presented an exploratory molecular analysis from the Phase III NIAGARA trial (4741RO), evaluating genomic alterations and transcriptome-defined subtypes in muscle-invasive bladder cancer (MIBC). Key findings: ▫️ Overall population: 24-month EFS was 68% with durvalumab plus neoadjuvant chemotherapy versus 60% with chemotherapy alone (HR 0.68; 95% CI 0.56–0.82). ▫️ Genomic subgroups: EFS HRs numerically favoured durvalumab in TP53-mutated (HR 0.51), FGFR3-mutated (HR 0.24), and TMB-high tumours (HR 0.44). ▫️ Molecular subtypes: EFS HRs favoured durvalumab in basal-squamous (HR 0.47; 95% CI 0.20–1.11), luminal (HR 0.52), and luminal-infiltrated (HR 0.67) subgroups, but not in the luminal-papillary subgroup (HR 1.35). Takeaway: Exploratory findings suggest broadly favourable EFS outcomes with perioperative durvalumab across multiple molecular subgroups. These analyses were not alpha-controlled and require cautious interpretation. @tompowles1 @ZakhariaYousef @oncodaily @myESMO oncodaily.com/genitourinary-… #ESMO26 #ESMO2026 #NIAGARA

Phase Ib/II EV-103: Long-Term Outcomes With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer At #ESMO26, Jose Pablo Maroto Rey presented long-term results from EV-103/KEYNOTE-869 (4740RO), evaluating first-line enfortumab vedotin (EV) with or without pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. Key findings: ▫️ EV + pembrolizumab (pooled DE/A/K; n=121): Median DOR was 29.6 months, median PFS was 10.4 months, and median OS was 27.7 months. ▫️ Five-year OS: 33.0% in the pooled EV + pembrolizumab cohorts and 23.9% in the EV monotherapy cohort (K; n=73). ▫️ Grade ≥3 treatment-related AEs: 64.5% with EV + pembrolizumab and 47.9% with EV monotherapy. No new safety signals were observed. Takeaway: Long-term follow-up demonstrated sustained responses and survival with first-line EV plus pembrolizumab. No formal between-arm statistical comparisons were performed in Cohort K. @oncodaily @myESMO @tompowles1 @DrRosenbergMSK oncodaily.com/genitourinary-… #ESMO26 #ESMO2026 #EV103